Could a celery seed extract help prevent another stroke?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1.Inclusion Criteria: 1. Age between 40 and 80 years old. 2. NIHSS score 0-5 at the time of stroke diagnosis, with MRI-confirmed acute ischemic infarct. 3. Time from stroke onset to enrollment ≤ 2 weeks. 4. Pre-stroke mRS score ≤ 1. 5. No prior diagnosis of cognitive impairment or dementia. 6. Informed consent must be voluntarily signed by the patient or their legal representative. Exclusion Criteria: 1. Based on the TOAST classification, consider cardioembolic stroke, stroke of other determined etiology, or stroke of undetermined etiology. 2. Intracranial hemorrhagic diseases on imaging: hemorrhagic stroke, epidural hematoma, subarachnoid hemorrhage, etc. (If hemorrhagic transformation is present, eligibility is at investigator's discretion.) 3. Carotid artery stenosis \> 50% requiring surgical intervention. 4. Systemic diseases causing cognitive impairment (e.g., endocrine diseases, vitamin deficiency, systemic autoimmune diseases). 5. Neurological disorders causing cognitive impairment, such as CNS infections, Creutzfeldt-Jakob disease, primary Parkinson's disease, traumatic brain injury, epilepsy, brain tumors. 6. Pre-stroke diagnosis of severe psychiatric disorders, including but not limited to depression, non-vascular cognitive impairment, or dementia (e.g., Alzheimer's disease, Parkinson's disease dementia, Lewy body dementia, frontotemporal dementia, drug or alcohol-induced cognitive impairment). 7. Severe hemiplegia and aphasia that significantly affect cognitive assessment. 8. Use of cognitive-enhancing drugs within 4 weeks before screening, including cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine), sodium oligomannate (GV-971), or monoclonal antibodies (lecanemab, donanemab, aducanumab). 9. Severe liver disease (e.g., acute hepatitis, active chronic hepatitis, cirrhosis) or ALT/AST \> 2× ULN. 10. Severe kidney disease or renal impairment (serum creatinine \> 1.5× ULN). 11. Coagulation disorders or thrombocytopenia (platelet count \< 100 × 10⁹/L). 12. Severe systemic diseases with an expected survival \< 1 year. 13. Contraindications for MRI or inability to complete MRI scan. 14. Allergy to butylphthalide. 15. Pregnancy, lactation, or planned pregnancy. 16. Participation in another clinical trial within 30 days before randomization. 17. Deemed unsuitable for the study by the investigator.